Trial Profile
A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Nov 2019
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 24 Jan 2018 According to Eli Lilly media release, based on the data from this study, Health Canada has issued a Notice of Compliance with Conditions for Olaratumab used in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma when treatment with radiation or surgery are not options.
- 19 Oct 2016 Results published in the Media Release
- 19 Oct 2016 Results published in Eli Lilly and Company media release.